학술논문
Histiocytic sarcoma arising in a child affected by Burkitt lymphoma, with t(8;14)(q24;q32) positivity in both tumors.
Document Type
Article
Author
d'Amore, Emanuele S.G; Mainardi, Chiara; Mussolin, Lara; Carraro, Elisa; Alaggio, Rita; Lazzari, Elena; Fusetti, Stefano; Ghirotto, Cristina; Marzollo, Antonio; Biddeci, Giada; Toffolutti, Tiziana; Massano, Davide; Scarzello, Giovanni; Zuliani, Monica; Putti, Maria Caterina; Biffi, Alessandra; Pillon, Marta
Source
Subject
*RETICULUM cell sarcoma
*PROGNOSIS
*TUMORS
*LYMPHOMAS
*BURKITT'S lymphoma
*DIAGNOSIS
*
*
*
*
*
Language
ISSN
0888-0018
Abstract
It is envisioned that the recently developed single-cell RNA-sequencing technologies will be a valuable asset in the next future to investigate the sub clonal heterogeneity or the cell of origin in these rare tumor cases and to assist the design of regimens for personalized tumor therapies. True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Keywords: Burkitt's lymphoma; histiocityc sarcoma; child EN Burkitt's lymphoma histiocityc sarcoma child 1 7 7 03/16/21 20210201 NES 210201 Malignant histiocytoses (MHs) are a group of accessory cell-derived neoplasms, traditionally sub-classified into histiocytic sarcoma, interdigitating cell sarcoma, Langerhans cell (LC) sarcoma and indeterminate cell sarcoma.[1] MHs with features of so-called histiocytic sarcoma (MH-HS) are malignant tumors expressing the histiocytic markers CD68, CD163 and Lysozyme, with negativity for both LC (S100, CD1a), follicular dendritc cell (CD23, CD21 and CD35), interdigitating cell (S100) and myeloid cell (MPO, CD13) markers.[1],[2] Few pediatric cases of MH-HS are reported.[3] These tumors have an aggressive clinical course and can arise either I de novo i or as a second malignancy.[4] Given their rarity, there is no consensus about the optimal treatment of MH-HS, and lymphoma-based protocols are widely used. [Extracted from the article]